Partner With Us NRI

SBI ETF BSE 100 share Price

Company details

6M Return -
1Y Return -
Mkt Cap.(Cr) -
Volume -
Div Yield 0.00%
OI Chg %
Volume -

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Procter & Gamble Health announced Q4FY23 & FY23 results:

  • Q4FY23:
    • Reported a sale of Rs 306.6 crore up by about 3% versus Q4FY22.
    • The sales grew at low single digit against the headwinds of slowing down of the category in Q4FY23.
    • The company reported a PAT of Rs 29.8 crore, a decline of 28% against Q4FY22 on account of higher material costs and one-time employee costs.
  • FY23:
    • The company has recorded a strong performance with sales of Rs 1,206 crore, up by 10% vs. FY22.
    • Profit after tax (PAT) for FY23 is Rs 229 crore, up by 19% versus FY22.
    • The board of directors has recommended a final dividend of Rs 50 per equity share, for FY23.

“We continued our efforts towards brand and category development and thus delivered a strong performance in the fiscal, marked by consistent growth across all our brands. The quarter, however, witnessed a category slowdown across our portfolio. Despite these challenges, we continued our commitment to our strategy of five integrated choices: a portfolio of daily-use products where performance drives brand choice; superiority across product, package, brand communication, retail execution, and value; productivity; constructive disruption of the entire value chain; and a highly efficient and effective organization structure.

We raised awareness and education among our consumers through initiatives like Neuropathy Awareness Week, wherein leading Global Health Experts converged to address the growing Public Health Concern of Peripheral Neuropathy. This also reinforced our efforts towards building an ecosystem for scientific collaboration and knowledge-sharing among healthcare professionals.

We also commemorated World Health Day by launching the Pragati Utsav, an initiative to raise awareness and empower the healthcare professionals of rural hinterlands, on Vitamin B deficiency. We bolstered our go-to-market strategy and strengthened our partnerships across omni-channel stores, increasing the availability and access of our brands across online and offline platforms, thereby helping meet the needs of our consumers and customers.

We launched the first-of-its-kind policies for employees, including the end-to-end support for children with special needs and a co-pay India Day Care policy, We continued to foster an environment of equal opportunities at the workplace. SEHAT, our flagship CSR program, continued to remain a priority during this fiscal year where we continued to strengthen public health through our strategic initiatives,” said Milind Thatte, Managing Director, Procter & Gamble Health.


Result PDF

View Other Company Results


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax



SBI ETF BSE 100 Information

Stock PE (TTM)
Promoter Holding
Book Value

No Data Found

AGM Date (Month) :
Face Value Equity Shares :
Market Lot Equity Shares :
BSE Code : 539031
NSE Code :
Book Closure Date (Month) :
BSE Group :
ISIN : INF200KA1572

FAQ’s on SBI ETF BSE 100 Shares

You can buy SBI ETF BSE 100 shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy SBI ETF BSE 100 Share.

Company share prices and volatile and keep changing according to the market conditions. As of the closing price of SBI ETF BSE 100 was ₹ -.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of , the market cap of SBI ETF BSE 100 stood at ₹ 0.00.

The latest PE ratio of SBI ETF BSE 100 as of is 0

The latest PB ratio of SBI ETF BSE 100 as of is 0.40

The 52-week high of SBI ETF BSE 100 is ₹ 0 while the 52-week low is ₹ 0

Download Our App

market app
market app